[HTML][HTML] Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data

M Alalawneh, O Rachid, I Abdallah, A Mahfouz… - European Journal of …, 2023 - Springer
… /PD) data available for rivaroxaban in extreme weight patients, which … based on BMI
categorization using real-world data in Qatar. … real-world evidence demonstrating that patients with …

Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population

JS Berger, F Laliberté, A Kharat, D Lejeune… - Current Medical …, 2021 - Taylor & Francis
… However, real-world data are needed to better assess the potential clinical benefits and …
(NVAF) patients with obesity. Thus, our objectives were to assess the real-world effectiveness …

[HTML][HTML] Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18-month prospective study

D Nikolic, AM Patti, RV Giglio, R Chianetta… - Diabetes Therapy, 2022 - Springer
… clinical trials, but data from real-world settings are … real-world effect of liraglutide on metabolic
parameters over an 18-month treatment period by comparing obese vs non-obese patients

Clinical performance of nonvitamin K antagonist oral anticoagulants in real-world obese patients with atrial fibrillation

V Russo, R Bottino, A Rago, AA Papa… - … in Thrombosis and …, 2020 - thieme-connect.com
data in the literature regarding performance of NOACs in obese patients with AF in the “real
world.” … VKA therapy in obese AF patients in a “real-world” setting. Here, we have considered …

Obese, non-eosinophilic asthma: frequent exacerbators in a real-world setting

S Ananth, A Navarra, R Vancheeswaran - Journal of Asthma, 2022 - Taylor & Francis
… Obese asthmatics have more exacerbations than non-obese asthmatics, even after adjusting
for confounding factors (such as smoking history, demographics and presence of GERD) (…

[HTML][HTML] Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity

B Navarro-Almenzar, JJ Cerezo-Manchado… - IJC Heart & …, 2021 - Elsevier
… seen in both the obese and non-obese populations and it may be … patients with morbid
obesity), however, it is a similar number to that included in clinical trials, taken to the real world, …

Obese patients gain less weight than non-obese patients when treated with insulin, with similar HbA (1c) reduction: new evidence from real-world data in type 2 …

S Paul, J Shaw, K Klein - DIABETOLOGIA, 2016 - edge.conference2web.com
… the first real-world evidence on three crucial aspects in insulin treated type 2 diabetes patients:
(… lower in obese patients over 2 years post insulin initiation, compared to that observed in …

A real-world exploration into clinical outcomes of direct oral anticoagulant dosing regimens in morbidly obese patients using data-driven approaches

EM Nwanosike, W Sunter, MA Ansari… - American Journal of …, 2023 - Springer
… EHR data from real-world patients to optimise clinical outcomes for morbidly obese patients
… In addition, real-world data were leveraged in the study. Several limitations could affect the …

[HTML][HTML] Characterization of an obese population: a retrospective longitudinal study from real-world data in northern Portugal

R Páscoa, A Teixeira, TS Henriques, H Monteiro… - BMC Primary …, 2023 - Springer
… including a comparison with a non-obese population. … to Portugal and has real-world data
on obesity not previously studied … The real-world data comparisons between T82 and non-T82 …

[HTML][HTML] Pulmonary Vein Isolation in Obese Compared to Non-Obese Patients: Real-Life Experience from a Large Tertiary Center

J Wolfes, D Hoppe, C Ellermann, K Willy… - Journal of …, 2022 - mdpi.com
… However, this concern is not supported by published data; in addition, our collective showed
a higher rate of pericardial effusions in the non-obese patients, which is an observation that …